Altuviiio logo



Resources for your patients

ALTUVIIIO offers a range of helpful resources and access programs for your patients

Getting patients started: Support and financial assistance

Switch support for you and your patients.

  • Patients get their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription
  • While you and the patient are deciding what treatment is right for them, a dedicated Sanofi Case Manager will review their health insurance information and coverage for ALTUVIIIO
  • Once the enrollment is complete, a dedicated Sanofi Case Manager will contact your patient within 24 hours with the next steps

  • Patients can access treatment even if their insurance is interrupted or they lack coverage
  • Complete the enrollment form with your patient and a dedicated Sanofi Case Manager will contact your patient within 24 hours to review your eligibility

  • Connects patients to disease education and other resources

  • Provides support and resources for your patients throughout their experience with ALTUVIIIO

To access these patient support programs, please download the enrollment form below.

Download Enrollment Form
Descargar el Formulario de Inscripción

Copay savings from ALTUVIIIO*

  • Patients may pay as little as $0 with maximum annual savings up to $20,000 with no income caps.
  • Help your patients get their copay card by completing the enrollment form with your patient or by asking them to contact their dedicated Sanofi case manager at 1-855-MyALTUVIIIO

Questions? Call 1-855-MyALTUVIIIO, Monday through Friday, 8 AM to 8 PM ET, or request a visit with an ALTUVIIIO Rep. They can connect you with a Case Manager, who can further explain what the ALTUVIIIO assistance programs can offer your patients.

*Copay Program not valid for patients utilizing Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs to pay in part or in full for their prescriptions. Savings may vary depending on patients’ out of pocket costs. Free Trial Plus valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free products dispensed through the Free Trial Plus or Factor Access Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid were prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.
Terms and conditions apply.

Tools for your patients


Infusion Overview


Doctor Discussion Guide


ALTUVIIIO Patient Brochure: An Overview

Keep track of hemophilia with the MicroHealth app

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia. MicroHealth is an app specifically designed to help patients with hemophilia track their treatment and progress and share this information with healthcare providers.

Download MicroHealth Brochure
Microhealth app

Ready to talk about ALTUVIIIO?

Set up time to talk with an ALTUVIIIO Representative to get to know ALTUVIIIO better.


Resources for HCPs

Learn about resources and tools for your practice as well as billing and coding information for ALTUVIIIO.


ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, may occur with ALTUVIIIO. Allergic-type hypersensitivity reactions were not reported in the clinical trials. Advise patients to discontinue use of ALTUVIIIO if hypersensitivity symptoms occur and contact a physician and/or seek immediate emergency care.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

IndicationImportant Safety Information

© 2024 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate.

MAT-US-2403562-v1.0-05/2024 Last Updated: May 2024